Efficacious but insidious: A retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients

Experimental Hematology

Volumn 37, Issue 11, 2009, Pages 1266-1273

  Janikova, Andrea ^a   Koristek, Zdenek ^a   Vinklarkova, Jaroslava ^b   Pavlik, Tomas ^a   Sticha, Michal ^a   Navratil, Milan ^a   Kral, Zdenek ^a   Vasova, Ingrid ^a   Mayer, Jiri ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b University Hospital   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CELL COUNT; COLONY FORMING UNIT GM; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL; HEMOLYSIS; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW DISEASES; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROCARBAZINE; RETROSPECTIVE STUDIES; VIDARABINE; VINCRISTINE;

EID: 70349989938     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.07.011     Document Type: Article

References (54)

1. Horning S.J. Natural history of and therapy for the indolent non-Hodgkińs lymphomas. Semin Oncol 20 (1993) 75-88
2. Johnson P.W., Rohatiner A.Z., Whelan J.S., et al. Patterns of survival in patients with current follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13 (1995) 140-147
3. Hiddemann W., Kneba M., Dreyling M., et al. Fronline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: tesults of prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
4. Marcus R., Imrie K., Solal-Celigny P., et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26 (2008) 4579-4586
5. Emmanouilides C., Rosen P., Rasti S., Territo M., and Kunkel L. Treatment of indolent lymphoma with fludarabine-mitoxantron: a phase II trial. Hematol Oncol 16 (1998) 107-116
6. McLaughlin P., Hagemeister F.B., Romaguera J.E., et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14 (1996) 1262-1268
7. Montoto S., Moreno C., Domingo-Domenech E., et al. High clinical and molecular responses rates with fludarabine, cyclophopshamide and mitoxantrone in previously untreated patients with advanced stage of follicular lymphoma. Haematologica 93 (2008) 207-214
8. Tsimberidou A.M., McLaughlin P., Younes A., et al. Fludarabine, mitoxantron, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100 (2002) 4351-4357
9. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114 (2001) 800-809
10. Sacchi S., Pozzi S., Marcheselli R., et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 110 (2007) 121-128
11. McLaughlin P., Estey E., Glassman A., et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105 (2005) 4573-4575
12. Tsimberidou A.M., Younes A., Romaguera J., et al. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104 (2005) 345-353
13. Brice P., Simon D., Bouabdallah R., et al. High-dose therapy with autologous stem cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11 (2000) 1585-1590
14. Horning S.J., Negrin R.S., Hoppe R.T., et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97 (2001) 404-409
15. Ketterer N., Salles G., Moullet I., et al. Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 103 (1998) 235-242
16. Laszlo D., Galieni P., Raspadori D., et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin lymphoma patients. Leuk Lymphoma 37 (2000) 157-161
17. Visani G., Lemoli R.M., Tosi P., et al. Fludarabine containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 105 (1999) 775-779
18. Watts M.J., Sullivan A.M., Leverett D., et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 4 (1998) 1554-1560
19. Michallet M., Thiebaut A., Dreger P., et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 108 (2000) 595-601
20. Sala R., Mauro F.R., Bellucci R., et al. Evaluation of marrow and blood haematopoietic progenitors in chronic lymphocytic leukemia before and after chemotherapy. Eur J Haematol 61 (1998) 14-20
21. Moskowitz C.H., Glassman J.R., Wuest D., et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4 (1998) 311-316
22. Dexter T.M., Allen T.D., and Lajtha L.G. Conditions controlling proliferation of haematopoietic stem cells in vitro. J Cell Physiol 91 (1977) 335-344
23. Gordon M.Y. Biology of haematopoietic stem cells. In: Wunder E.W., and Henon P.R. (Eds). Peripheral Blood Stem Autografts (1993), Springer Verlag, Berlin 26-34
24. Gordon M.Y. The bone marrow stromal microenvironment. In: Burnett A., Armitage J., Newland A., and Keating A. (Eds). Hematological Oncology (1994), Cambridge University Press, Cambridge 73-94
25. Sutherland H.J., Eaves C.J., Eaves A.C., Dragowska W., and Lansdorp P.M. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74 (1989) 1563-1570
26. Sutherland H.J., Lansdorp P.M., Henkelman D.H., Eaves A.C., and Eaves C.J. Functional characterisation of individual human hematopoietic stem cells cultured at limiting dilutions on supportive marrow stromal layers. Proc Natl Acad Sci U S A 87 (1990) 3584-3588
27. Kořístek Z., and Mayer J. Bone marrow processing for transplantation using the COBE spectra cell separator. J Hematother Stem Cell Res 8 (1999) 443-448
28. Haas R., Mohle R., Fruhauf S., et al. Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83 (1994) 3787-3795
29. Kotasek D., Shepherd K.M., Sage R.E., et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in patients with lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9 (1992) 11-16
30. Wang J., Weiss L.M., Chang K.L., et al. Diagnostic utility of bilateral bone marrow examination. Cancer 94 (2002) 1522-1531
31. Harrison D.E., Astle C.M., and Stone M. Numbers and functions of transplantable primitive immunohematopoietic stem cells. Effect of age. J Immunol 142 (1989) 3833-3840
32. Liang Y., Van Zant G., and Szilvassy S.J. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 106 (2005) 1479-1487
33. Sudo K., Ema H., Morita Y., and Nakauchi H. Age-associated characteristics of murine hemopoietic stem cells. J Exp Med 192 (2000) 1273-1280
34. Boiret N., Kanold J., Bons J.M., et al. Granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells from children contain the same levels of long-term culture-initiating cells producing the same numbers of colony-forming cells as those from adults, but display greater in vitro monocyte/macrophage potential. Br J Haematol 112 (2001) 806-813
35. Tam C.S., Wolf M., Prince H.M., et al. Fludarabine, Cyclophosphamide, and Rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent Non-Hodgkin lymphoma. Cancer 106 (2006) 2412-2420
36. Stiff P., Micallef I., McCarthy P., et al. Treatment with plerixafor in non-Hodgkińs lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 15 (2009) 249-256
37. Zinzani P.L., Tani M., Pulsoni A., et al. Fludarabine and mitoxantrone followed by yttrium-90-ibritumomab tiuxetan in previously untreated patients with follicular lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 9 (2008) 352-358
38. Rocci A., Ricca I., Dellacasa C., et al. Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. Exp Hematol 35 (2007) 673-681
39. Crawley C.R., Foran J.M., Gupta R.K., et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 11 (2000) 861-865
40. Nickening C., Dreyling M., Hoster E., et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not overall survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas. Results of a prospective randomized trial of the German low-grade lymphoma. Cancer 107 (2006) 1014-1022
41. Hainsworth J.D., Burris H.A., Morrisey L.H., et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95 (2000) 3052-3056
42. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99 (2007) 706-714
43. Ghielmini M., Bosshard G., Pampallona S., Genini D., Bernier J., and Sessa C. Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors in vitro. Cell Biol Toxicol 15 (1999) 395-404
44. Schmidt-Hieber M., Busse A., Reufi B., Knauf W., Thiel E., and Blau I.W. Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. J Cancer Res Clin Oncol 135 (2009) 227-234
45. Berger M.G., Berger J., Richard C., et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia 22 (2008) 2131-2134
46. Kasper C., Ryder W.D., Durig J., et al. Content of long-term culture-initiating cells, clonogenic progenitors and CD34+ cells in apheresis harvest of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma. Br J Haematol 104 (1999) 374-381
47. Selleri C., Maciejewski J.P., De Rosa G., et al. Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant. Bone Marrow Transplant 23 (1999) 1029-1037
48. Uhlman D.L., Verfaillie C., Jones R.B., and Luikart S.D. BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis. Br J Haematol 78 (1991) 304-309
49. Yao M., Bouchet S., Harnois C., et al. Quantitative and qualitative alterations of long-term culture-initiating cells in patients with acute leukaemia in complete remission. Br J Haematol 103 (1998) 124-128
50. Liang R., Todd D., Chan T.K., Chiu E., Lie A., and Ho F. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkińs lymphoma. Hematol Oncol 11 (1993) 43-50
51. Glas M., Rasch K., Wiewrodt D., Weller M., and Herrlinger U. Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology 75 (2008) 182-185
52. Goerne R., Bogdahn U., and Hau P. Procarbazine-a traditional drug in the treatment of malignant gliomas. Curr Med Chem. 15 (2008) 1376-1387
53. Schmidt F., Fischer J., Herrlinger U., Dietz K., Dichgans J., and Weller M. PCV chemotherapy for recurrent glioblastoma. Neurology 66 (2006) 587-589
54. Wilde S., Jetter A., Rietbrock S., et al. Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkińs lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 46 (2007) 319-333